Mark is originally from Wisconsin, and graduated in 2002 with a B.S. in biology (with an emphasis in ecology and wildlife biology). He got his start in the drug development industry with Covance in 2003 as Study Technician working on large and small animal GLP toxicity studies. In 2005, he moved to Colorado and further increased his skill set by working his way up from Research Associate to Study Director, and assisting in the start-up as co-owner of a preclinical CRO specializing in toxicity and pharmacokinetic studies. In 2011, he continued his journey west to San Diego where he joined a preclinical CRO as a Study Director/Manager. Fascinated by the prospect of integrating technology with the traditional way of preclinical study conduct, he joined Vium in the bay area in 2015, and is now fortunate to be able to continue to pursue that fascination with Recursion Pharma with an overall goal of improving the lives of people suffering from debilitating disease. When not working, Mark enjoys spending time with his family, hiking, camping, fishing/hunting, and hanging out at the beach.
Are you Recursion ready?
Join our passionate, innovative team—and help us realize our goal of 100 treatments by 2025.